Background

The FDA public workshop was convened to address the challenges of designing and operating registries that evaluate the safety of drugs and biologics used during pregnancy. Recent increases in medication use among pregnant women have highlighted a paucity of data. Limited systematic evidence on drug exposure in pregnancy makes it difficult for regulators and pharmaceutical companies to demonstrate safety.

Challenges

The primary difficulty in establishing a registry is the small number of cases and ethical constraints that limit data collection. In addition, data standardization and long‑term follow‑up are problematic, creating uncertainty in result interpretation. In this context, a "registry" refers to a database that systematically records drug exposure and outcomes during pregnancy. These issues directly affect patient safety and drug labeling.

Innovative Approaches

The workshop presented novel methods that leverage real‑time data capture and digital health tools. Integration with electronic health records (EHR) and mobile applications can enhance patient self‑reporting and improve data quality. More accurate and timely data can accelerate regulatory approvals and build confidence in the use of medications during pregnancy.

Market and Industry Implications

Improved registries enable pharmaceutical companies to update pregnancy labeling more rapidly and expand market access. Investors may need to reassess risk‑management considerations for companies capable of generating robust pregnancy safety data. Regulators are also more likely to revise guidance based on stronger scientific evidence.